The pharmaceutical industry and CROs have been struggling with a number of challenges since the outbreak of Coronavirus (COVID-19), and the one topping the list which is to ensure the continuity of trials. With the emerging hurdles of enrollment, study start-up, patient retention and site visits, the situation calls for alternative models to be employed by sponsors, such as using advanced technologies, which help the companies to shake off inertia and ensure the continuity of trials with minimal losses and the highest compliance. In their recent series of guidance the FDA, EMA, and regional Ministries of Health encourage the retention of the continuity of launched trials, and to resort to virtualizing the trials as much as possible under the circumstances. Moreover, in its rec

Join for free to read